6-amino-1-hydroxyhexane-1,1-diphosphonate has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anastasi, G; Atteritano, M; Catalano, A; Frisina, N; Gaudio, A; Lasco, A; Melloni, D; Morabito, N; Trifiletti, A | 1 |
| Anastasi, G; Franchina, F; Frisina, N; Galì, A; Gaudio, A; Magno, C; Maisano, D; Melloni, D; Morabito, N | 1 |
2 trial(s) available for 6-amino-1-hydroxyhexane-1,1-diphosphonate and Cancer of Prostate
| Article | Year |
|---|---|
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Density; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate | 2004 |
Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Amino Acids; Androgen Antagonists; Anilides; Biomarkers; Bone Density; Calcium; Chromatography, High Pressure Liquid; Diphosphonates; Drug Therapy, Combination; Estradiol; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Nitriles; Osteoporosis; Parathyroid Hormone; Phosphorus; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Outcome; Vitamin D | 2005 |